)
Expertise
Always Striving for Better
We are a biotechnology leader with an ever-evolving portfolio of lifesaving products, built from a never-ending passion to always put patients and people first. Whether the goal is to improve an existing therapy or invent a new treatment, we commit to delivering what we say we will, better than before, every day. Now, with CSL Vifor, our collective expertise reaches even further to where the next discovery can be found. We’re after better answers. Always.
-
US $1.16 billion
was invested in R&D in 2020/21 across our businesses
-
US $4.6 billion
in R&D investments in last 5 years
-
>2,000
Research & Development employees
Areas of Expertise
Every day, CSL is reaching for better solutions. Our four areas of focus and exploration—rare and serious diseases (CSL Behring), influenza vaccines (CSL Seqirus), plasma collection (CSL Plasma) and therapies for iron deficiency and nephrology (CSL Vifor)—are leading the way in biotechnology.
Rare & Serious Diseases
We are committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. This commitment is reflected in our support of programs and activities for people with deficient or malfunctioning blood proteins that cause diseases like bleeding disorders, primary immune deficiencies and Alpha1-proteinase inhibitor deficiencies.
A continual focus on innovation in new products, improved products and manufacturing know-how is the key to future growth.
Vaccines
CSL Seqirus is one of the largest influenza vaccine providers in the world, with sales and operations in more than 20 countries. CSL Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe and Australia.
In addition to providing influenza vaccines worldwide, CSL Seqirus manufactures, sells and distributes a comprehensive range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. We also manufacture and market in vitro diagnostic products through immunohaematology. In 2021, CSL Seqirus partnered to advance the development of a novel immunotherapy targeting COVID-19.
Iron Deficiency and Nephrology
CSL Vifor has been a pioneer in the development of iron-based products and has established itself as a global leader in the treatment of iron deficiency . Our leadership is built on our scientific, regulatory and commercial expertise, resulting in the creation of globally trusted brands. We partner with specialists to improve the lives of patients with high unmet medical need and, through our innovative portfolio and individualized solutions, we aim to address the full spectrum of kidney disease with a focus in rare disease.
